Yoo Y C, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
Adv Exp Med Biol. 1998;443:285-91. doi: 10.1007/978-1-4757-9068-9_35.
The effect of a bovine milk protein, lactoferrin (bLf), and a pepsin-generated peptide of bLf, lactoferricin (Lfcin-B), on inhibition of tumor metastasis produced by highly metastatic murine tumor cells, B16-BL6 melanoma and L5178Y-ML25 lymphoma cells, was examined in experimental and spontaneous metastasis models using syngeneic mice. The subcutaneous (s.c.) administration of bovine apo-lactoferrin (apo-bLf) and Lfcin-B 1 day after tumor inoculation significantly inhibited liver and spleen metastasis of L5178Y-ML25 cells and lung metastasis of B16-BL6 cells, whereas human apo-lactoferrin (apo-hLf) and bovine holo-lactoferrin (holo-Lf) at the dose of 1 mg/mouse did not. Furthermore, both apo-bLf and Lfcin-B, but not apo-hLf and holo-bLf, inhibited the number of tumor-induced blood vessels and suppressed tumor growth on day 8 after tumor inoculations in an in vivo model. However, in a long-term analysis of tumor growth for up to 21 days after tumor inoculation, single administration of apo-bLf significantly suppressed the growth of B16-BL6 cells throughout the examination period, but Lfcin-B showed inhibitory activity only during the early period (8 days). In spontaneous metastasis model, multiple administration of both apo-bLf and Lfcin-B significantly inhibited lung metastasis of B16-BL6 cells, however it was only apo-bLf that exhibited the inhibitory effect of tumor growth at the time of primary tumor amputation (on day 21) after tumor inoculation. The results suggest that apo-bLf and Lfcin-B inhibit tumor metastasis through different mechanisms, and that the inhibitory activity of bLf on tumor metastasis may be related to the property of iron (Fe3+)-saturation.
利用同基因小鼠,在实验性和自发性转移模型中,研究了牛乳蛋白乳铁蛋白(bLf)及其胃蛋白酶生成的肽乳铁素(Lfcin-B)对高转移性小鼠肿瘤细胞B16-BL6黑色素瘤细胞和L5178Y-ML25淋巴瘤细胞产生的肿瘤转移的抑制作用。肿瘤接种后1天皮下注射牛脱铁乳铁蛋白(apo-bLf)和Lfcin-B可显著抑制L5178Y-ML25细胞的肝和脾转移以及B16-BL6细胞的肺转移,而1mg/只小鼠剂量的人脱铁乳铁蛋白(apo-hLf)和牛全乳铁蛋白(holo-Lf)则无此作用。此外,在体内模型中,apo-bLf和Lfcin-B均可抑制肿瘤诱导的血管数量,并在肿瘤接种后第8天抑制肿瘤生长,而apo-hLf和holo-bLf则无此作用。然而,在肿瘤接种后长达21天的肿瘤生长长期分析中,单次注射apo-bLf在整个检测期均显著抑制B16-BL6细胞的生长,但Lfcin-B仅在早期(8天)显示出抑制活性。在自发性转移模型中,多次注射apo-bLf和Lfcin-B均可显著抑制B16-BL6细胞的肺转移,但只有apo-bLf在肿瘤接种后原发性肿瘤切除时(第21天)表现出肿瘤生长抑制作用。结果表明,apo-bLf和Lfcin-B通过不同机制抑制肿瘤转移,且bLf对肿瘤转移的抑制活性可能与铁(Fe3+)饱和特性有关。